Loading resource…

Città della Salute e della Scienza Hospital, Turin, Italy
In heart failure with reduced ejection fraction (HFrEF), despite guideline-directed therapy, patients continue to experience significant residual risk. The foundational treatment pillars include ARNI, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. This document reviews the latest evidence regarding vericiguat, a novel treatment option, and its integration into contemporary HFrEF management, highlighting findings from recent clinical trials and meta-analyses.
No account needed